Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Schroder Investment Management Group lowered its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 58.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,142 shares of the company's stock after selling 34,158 shares during the quarter. Schroder Investment Management Group's holdings in Axsome Therapeutics were worth $2,047,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of AXSM. Geode Capital Management LLC lifted its position in Axsome Therapeutics by 2.7% during the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company's stock valued at $81,659,000 after purchasing an additional 23,564 shares during the period. Wellington Management Group LLP raised its stake in Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock valued at $66,750,000 after buying an additional 8,125 shares during the last quarter. Norges Bank bought a new position in shares of Axsome Therapeutics during the 4th quarter valued at $34,100,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock worth $27,755,000 after buying an additional 5,438 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Axsome Therapeutics by 14.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after buying an additional 27,534 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Remove Ads

Axsome Therapeutics Price Performance

NASDAQ:AXSM traded up $2.41 on Friday, reaching $98.06. 867,734 shares of the company's stock traded hands, compared to its average volume of 678,891. The stock has a 50-day simple moving average of $119.51 and a 200-day simple moving average of $101.99. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $139.13. The firm has a market cap of $4.78 billion, a PE ratio of -16.37 and a beta of 0.88. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. Truist Financial increased their price objective on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Royal Bank of Canada raised their price objective on shares of Axsome Therapeutics from $143.00 to $192.00 and gave the stock an "outperform" rating in a report on Wednesday, February 19th. Leerink Partners boosted their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday, February 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $153.00 target price on shares of Axsome Therapeutics in a report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $169.80.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 22.40% of the company's stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.